scispace - formally typeset
P

Petr Protiva

Researcher at Yale University

Publications -  36
Citations -  1448

Petr Protiva is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 20, co-authored 26 publications receiving 1328 citations. Previous affiliations of Petr Protiva include Columbia University & University of Connecticut Health Center.

Papers
More filters
Journal ArticleDOI

Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury

TL;DR: HEV infection contributes to a small but important proportion of cases of acute liver injury that are suspected to be drug induced, andSerologic testing for HEV infection should be performed, particularly if clinical features are compatible with acute viral hepatitis.
Journal ArticleDOI

Reliability of the Roussel Uclaf Causality Assessment Method for Assessing Causality in Drug-Induced Liver Injury

TL;DR: The mediocre reliability of the R UCAM is problematic for future studies of drug‐induced liver injury and alternative methods, including modifying the RUCAM, developing drug‐specific instruments, or causality assessment based on expert opinion, may be more appropriate.
Journal ArticleDOI

Quantification of Adequate Bowel Preparation for Screening or Surveillance Colonoscopy in Men

TL;DR: Patients with BBPS scores of 2 or 3 for all colon segments have adequate bowel preparation for the detection of adenomas larger than 5 mm and should return for screening or surveillance colonoscopy at standard guideline-recommended intervals.
Journal ArticleDOI

Risk factors for sessile serrated adenomas.

TL;DR: The data suggest that smoking at least 20 pack-years is strongly associated with any and large SSAs and diabetes mellitus and obesity seem to be associated with SSAs as well, which has implications for CRC screening.
Journal ArticleDOI

Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells.

TL;DR: The data suggest that lovastatin induces morphologic changes and apoptosis by inhibiting geranylgeranylation of small GTPases of the rho family and thereby inactivating them.